The European Medicines Agency has acknowledged a request by Sanofi Genzyme to re-examine its refusal to qualify as a new active substance (NAS) Nexviadyme (avalglucosidase alfa), the company’s drug for Pompe disease that was recommended for pan-EU marketing approval last month.
The notification of re-examination is listed on the agenda of the latest monthly meeting of the EMA’s human medicines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?